Ho AD - Search Results

1

New developments in stem cell biology and therapy. First meeting report from the working group of the German Society for Hematology and Oncology.

Fruehauf S, Ho AD. Fruehauf S, et al. Among authors: ho ad. Cytotherapy. 2005;7(3):301-8. doi: 10.1080/14653240510027208. Cytotherapy. 2005. PMID: 16081357

2

Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients.

Fruehauf S, Schmitt K, Veldwijk MR, Topaly J, Benner A, Zeller WJ, Ho AD, Haas R. Fruehauf S, et al. Among authors: ho ad. Br J Haematol. 1999 Jun;105(3):786-94. doi: 10.1046/j.1365-2141.1999.01405.x. Br J Haematol. 1999. PMID: 10354148 Free article.

3

Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors.

Kasper B, Fruehauf S, Schiedlmeier B, Buchdunger E, Ho AD, Zeller WJ. Kasper B, et al. Among authors: ho ad. Cancer Chemother Pharmacol. 1999;44(5):433-8. doi: 10.1007/s002800051001. Cancer Chemother Pharmacol. 1999. PMID: 10501919

4

Pulmonary artery hypertension during interferon-alpha therapy for chronic myelogenous leukemia.

Fruehauf S, Steiger S, Topaly J, Ho AD. Fruehauf S, et al. Among authors: ho ad. Ann Hematol. 2001 May;80(5):308-10. doi: 10.1007/s002770100298. Ann Hematol. 2001. PMID: 11446736

5

The FBMD-1 stroma cell line secretes a unique moiety which can increase retroviral transduction of lineage-committed and primitive human peripheral blood progenitor cells.

Buss EC, Schiedlmeier B, Ho AD, Zeller WJ, Fruehauf S. Buss EC, et al. Among authors: ho ad. Cancer Gene Ther. 2001 Jun;8(6):440-9. doi: 10.1038/sj.cgt.7700324. Cancer Gene Ther. 2001. PMID: 11498764

6

Functional characterization of podia formation in normal and malignant hematopoietic cells.

Fruehauf S, Srbic K, Seggewiss R, Topaly J, Ho AD. Fruehauf S, et al. Among authors: ho ad. J Leukoc Biol. 2002 Mar;71(3):425-32. J Leukoc Biol. 2002. PMID: 11867680

7

Level of CD 20-expression and efficacy of rituximab treatment in patients with resistant or relapsing B-cell prolymphocytic leukemia and B-cell chronic lymphocytic leukemia.

Perz J, Topaly J, Fruehauf S, Hensel M, Ho AD. Perz J, et al. Among authors: ho ad. Leuk Lymphoma. 2002 Jan;43(1):149-51. doi: 10.1080/10428190210178. Leuk Lymphoma. 2002. PMID: 11908720

8

Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning.

Topaly J, Fruehauf S, Ho AD, Zeller WJ. Topaly J, et al. Among authors: ho ad. Br J Cancer. 2002 May 6;86(9):1487-93. doi: 10.1038/sj.bjc.6600242. Br J Cancer. 2002. PMID: 11986785 Free PMC article.

9

Retroviral vector integration occurs in preferred genomic targets of human bone marrow-repopulating cells.

Laufs S, Gentner B, Nagy KZ, Jauch A, Benner A, Naundorf S, Kuehlcke K, Schiedlmeier B, Ho AD, Zeller WJ, Fruehauf S. Laufs S, et al. Among authors: ho ad. Blood. 2003 Mar 15;101(6):2191-8. doi: 10.1182/blood-2002-02-0627. Epub 2002 Nov 7. Blood. 2003. PMID: 12424203 Free article.

10

Combination of imatinib and established antileukemic treatment modalities for otherwise refractory BCR-ABL positive lymphoblastic leukemia.

Fruehauf S, Topaly J, Buss EC, Schad M, Goerner M, Zeller WJ, Ho AD. Fruehauf S, et al. Among authors: ho ad. Haematologica. 2002 Dec;87(12):ECR38. Haematologica. 2002. PMID: 12495909 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

720 results

Search Page

Filters